Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: Fast Track - Respiratory Syncytial Virus Infections *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Codagenix
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: South Africa, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Respiratory Syncytial Virus Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CDX-RSV-101P | P1 |
Active, not recruiting |
Respiratory Syncytial Virus Infections |
2025-04-30 |